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Cytostatic anticancer drugs are known as carcinogenic, mutagenic, and teratogenic risk factors for health care workers occupation-
ally exposed. It has been demonstrated that the administration of interleukin-15 in rat models of colon carcinoma protects against
chemotherapy-induced gastrointestinal toxicities. We found that occupational exposure to chemotherapeutic antiblastic agents in
vivo modiﬁed circulating levels of interleukin-15 in 17 health care workers exposed to antineoplastic drugs in relation to their jobs
and in as many healthy age- and sex-matched subjects. Health care workers displayed signiﬁcantly higher circulating interleukin-15
levels compared to their age-matched controls. If this increase representing an anticancer response remains to be established, these
ﬁndings strengthen the idea of a therapeutic use of interleukin-15 in the ﬁeld of cancer.
Cytostatic anticancer drugs are known as carcino-
genic, mutagenic, and teratogenic risk factors for health
care workers who are occupationally exposed during
preparation and management of such drugs, absorbing
these substances mainly through inhalation or dermal
contact. Risk assessment for occupational exposure to
antiblastic chemotherapeutic drugs is carried out by
means of environmental and biological monitoring [1].
To reduce these risks during the last twenty years, several
researchers have developed and validated methods for
monitoring occupational exposure to such agents. In
Italy, for example, a working group, Prevention of Oc-
cupational Risks Due to Handling Antineoplastic Drugs
in Health Care, was established by the Italian Institute of
Prevention and Safety at Work (Istituto Superiore per la
Prevenzione e Sicurezza sul Lavoro (ISPESL)) in February
1995 to make recommendations for environmental and
biological monitoring of exposure and health surveil-
lance, and develop guidelines for primary and secondary
prevention [2].
Interleukin (IL)-15 is a T cell growing factor impli-
cated in inﬂammatory response of the host. It plays a
key role in development, diﬀerentiation, and function of
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B and T lymphocytes, natural killer (NK) cells, NK-T
cells, macrophages,and monocytes [3]. IL-15 has biologic
properties in vitro similar to IL-2, consistent with their
shared receptor signaling component [3]. It was demon-
strated that the administration of IL-15 in rat models of
colon carcinoma protects against chemotherapy-induced
gastrointestinal toxicities (reviewed in [3]).
In light of these ﬁndings, we found that occupational
exposure to chemotherapeutic antiblastic agents modiﬁes
in vivo circulating levels of IL-15.
We studied 17 health care workers cases (11 men and
5w o m e n )( G r o u pA )w i t ham e a na g e± SD 42.29 ± 6.08
years, who had been exposed to antineoplastic drugs in
relation to their jobs for 13.25±8.16 years. The task of the
health care workers under study was the preparation and
administration of theantineoplastic drugsattheoncolog-
ical and hematological centers of two city hospitals.
A questionnaire was used to obtain information on
medical and occupational history, drug usage, and smok-
ing and drinking habits.
Seventeen healthy age- and sex-matched subjects
(Group B), with a negative history for exposure to anti-
neoplastic drugs, were also enrolled as controls.
Exclusion criteria in both groups were the following:
inﬂammatory, immunologic, oncologic, or other serious
diseases for which the patients have taken drugs likely to
interfere with the study.
All subjects gave their informed written consent to
participate in the study.2005:1 (2005) Interleukin-15 in Workers Exposed to Chemotherapeutic Agents 61
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Figure 1. IL-15 serum levels in workers exposed to chemother-
apeutic antiblastic agents (Group A), and in healthy donors
(Group B). Results, expressed as mean ± standard deviations,
are from individual measurements in duplicate.
A 10mL blood sample was collected from the
antecubital vein, allowed to clot at room temperature
for 2hours, separate by centrifugation at 200xg for
15minutes in a 4235 A centrifuge (ALC Int. SRL, Milan,
Italy) and stored at 80◦C until use.
SerumIL-15levelswereassayedbyimmunoenzymatic
methods (Quantikine Human IL-15, ELISA-kits, R&D
System, SPACE Import-Export, Milan, Italy). The mini-
mum detectable dose of IL-15 is less than 2pg/mL.
Diﬀerences in serum levels were assessed by one way
analysis of variance (ANOVA) and Student-Newman-
Keuls test. Data were expressed as mean ± SD). A value
of P<. 05 was considered signiﬁcant.
Figure 1 shows that group A subjects displayed sig-
niﬁcantly higher circulating IL-15 levels compared to
their age-matched controls (3.15 ± 1.88 versus 1.87 ±
89.16pg/mL, P<. 05).
No signiﬁcant correlation was found between IL-15
serum levels and age and duration of antineoplastic drugs
exposure.
IL-15 is known to improve the in vivo antitumor ac-
tivity of adoptively transferred CD8+ T cells; in fact it
helps to maintain a memory CD8+ T cell population and
can inhibit apoptosis [4] .M o r e o v e r ,i tw a sf o u n dt h a te n -
dogenous production of IL-15, but not IL-2, by a tumor-
bearing host enhanced the in vivo antitumor eﬃcacy of
adoptively transferred CD8+ T cells [4].
TwostudiesdemonstratedthatIL-15isabletoprovide
signiﬁcant protection from intestinal toxicity of two dif-
ferent chemotherapeutic agents, irinotecan (CPT-11) (re-
viewed in [3]) and 5-ﬂuorouracil (reviewed in [3]) with
maintenance and potentiation of antitumor activity, and
an increased therapeutic index of the drugs administered.
In addition, it was demonstrated that IL-15 administra-
tion associated with cyclophosphamide (CY) injection in
a mouse lung tumor model resulted in a signiﬁcant pro-
longation of life [5]. For successful CY + IL-15 therapy,
the presence of NK and T lymphocytes seems to be neces-
sary [5].
In the present study we found signiﬁcantly higher
serum levels of IL-15 in subjects with occupational
exposure, during preparation and administration, to
chemotherapeutic antiblastic drugs, with respect to non-
exposed subjects. To the best of our knowledge there are
no reports about the involvement of immune system dur-
ing or after antiblastic drugs exposure in humans.
It is known that occupational exposure to antineo-
plasticagentsmaycausecarcinogenic,mutagenic,andter-
atogeniceﬀects,thereforethereis,today,ageneralconsen-
sus on the necessity of monitoring occupational exposure
to such agents. Health care workers of our study had an
exposure time covering also the years before the guide-
lines application. Thus, it might be hypothesized that the
increase of IL-15 that we found may be the expression of
an endogenous production by human cells as antitumor
response.
It is known that immunotherapy with IL-2 has been
used extensively for the treatment of patients with can-
cer, even if some qualities may preclude it from being
the optimal T cell growth/activation factor for use in im-
munotherapy [4]. IL-15 and IL-2 share similar properties
and utilize the same aﬃnity receptor complex, although
they can play diﬀerent, and at times oppositional, roles
in T cell biology. Moreover, in murine models comparing
treatment with IL-15 and IL-2 for eﬃcacy against experi-
mental lung metastasis, IL-15 showed a higher therapeu-
tic index and a lower toxicity than IL-2 (reviewed in [3]).
Therefore,it may be speculated that in a near future the in
vivo antitumor activity of IL-15 in mice may be translated
in humans.
In conclusion, here we provide the ﬁrst evidence of a
strong increase in circulating IL-15 in subjects with occu-
pational exposure to chemotherapeutic antiblastic drugs.
Ifthisincreaserepresentingananticancerresponsere-
mains to be established, these ﬁndings strengthen the idea
of a therapeutic use of IL-15 in the ﬁeld of cancer.
REFERENCES
[1] Merler E, Villa L, Lucchini R. Pathological eﬀects due
to antineoplastic drugs in workers engaged in their
production, preparation or administration. Med Lav.
1996;87(3):207–221.
[2] Alessio L, Apostoli P, Draicchio F, et al. Prevention
of risks from occupational exposures to antineoplas-
ticdrugs: consensus document. Int J Occup Environ
Health. 1997;3(1):84.
[3] Fehniger TA, Caligiuri MA. Interleukin 15: bi-
ology and relevance to human disease. Blood.
2001;97(1):14–32.
[4] Klebanoﬀ CA, Finkelstein SE, Surman DR, et al. IL-
15 enhances the in vivo antitumor activity of tumor-
reactive CD8+ T cells. Proc Natl Acad Sci U S A.
2004;101(7):1969–1974.
[5] Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ,
Evans R. Combination chemotherapy and IL-15 ad-62 Giovanna Spatari et al 2005:1 (2005)
ministration induce permanent tumor regression
in a mouse lung tumor model: NK and T cell-
mediated eﬀects antagonized by B cells. JI m m u n o l .
1998;161(12):6977–6984.